Merck's Dual Setback and Success — How It Reshapes Pharma Portfolios and Sector Rotation

On 3 May 2026, Merck announced the termination of its Phase 2 lung‑cancer trial of the KRAS‑targeted inhibitor MRTX‑1133, citing insufficient efficacy (Confirmed — Merck press release). Two weeks later, on 17 May 2026, Merck and Gilead disclosed that their co‑developed long‑acting HIV regimen, Biktarvy‑XR, achieved a 92% viral suppression rate in Phase 3 (Confirmed — joint company statement).

Discontinued Lung‑Cancer Trial Erases Near‑Term Revenue Upside — Pressure on Oncology‑Heavy Stocks

The lung‑cancer study represented Merck’s most ambitious late‑stage oncology play since its 2022 Keytruda expansion. Analysts at Cowen projected $1.2 billion in incremental sales by 2032 if the trial had succeeded (Analyst view — Cowen, 3 May 2026). With the trial halted, that upside evaporates, dragging Merck’s projected oncology growth rate from 7% to 4% year‑over‑year (Goldman Sachs strategist Jan Hatzius, in a note to clients 4 May 2026).

Beyond Merck, the setback reverberates across the KRAS‑targeted drug space. Mirati Therapeutics, whose KRAS inhibitor sotorasib is already FDA‑approved, saw its stock dip 6% on 4 May 2026 as investors reassessed the class’s risk profile (Bloomberg, 4 May 2026). The broader implication is a potential rotation out of high‑risk, single‑target oncology bets toward diversified biopharma with multiple revenue streams.

Positive HIV Phase 3 Results Ignite Growth Narrative — Boost for Gilead and Partner‑Heavy Portfolios

The HIV combo achieved a 92% suppression rate at week 48, surpassing the 85% benchmark set by existing regimens (Confirmed — joint company statement). Gilead’s CFO, Daniel O'Day, projected $2.5 billion in cumulative sales by 2032, assuming a 15% market share in the U.S. HIV market (Analyst view — JPMorgan, 18 May 2026).

Investors are likely to re‑price Gilead’s earnings outlook upward. In the week following the announcement, GILD shares rose 4.3% to $78.90, their highest level since March 2026 (NASDAQ, 19 May 2026). The success also validates Merck’s partnership model, suggesting that future co‑development deals could be a reliable earnings engine.

Sector Rotation Signals — From Single‑Target Oncology to Broad‑Based Biotech and Diversified Pharma

Historically, a high‑profile oncology failure triggers a short‑term sell‑off in biotech ETFs, but the magnitude depends on the failure’s scope. The MRTX‑1133 termination removed roughly $300 million of projected 2026 revenue from Merck’s pipeline (Analyst view — Morgan Stanley, 5 May 2026), a figure that dwarfs the $45 million loss from a typical biotech miss.

Consequently, investors are reallocating toward diversified drugmakers like Pfizer (PFE) and Johnson & Johnson (JNJ), whose pipelines span vaccines, immunology, and rare diseases. On 6 May 2026, PFE gained 2.1% while JNJ added 1.8%, reflecting the shift (Yahoo Finance, 6 May 2026). Simultaneously, pure‑play oncology ETFs such as iShares Nasdaq Biotechnology (IBB) fell 3% as capital fled high‑risk bets.

Portfolio Positioning — Hedge the Oncology Gap, Leverage the HIV Upside

For a balanced biotech exposure, consider a two‑pronged approach: trim exposure to KRAS‑centric stocks and increase weight in companies with diversified pipelines and proven partnership revenues. Adding a modest allocation to Gilead’s stock or its preferred‑share series (GILD‑P) captures the HIV upside while limiting downside risk.

Fixed‑income investors may also benefit. The FDA’s accelerated approval pathway for HIV therapies has historically lowered credit risk for drugmakers with strong HIV franchises, tightening spreads on corporate bonds issued by firms like Gilead and ViiV Healthcare (Analyst view — Bank of America, 20 May 2026).

Long‑Term Implications — How Merck’s R&D Strategy May Evolve

Merck’s decision to cut the KRAS trial signals a possible strategic pivot toward partnership‑driven development. The company now has three late‑stage collaborations, including the HIV combo and a hepatitis C program with Alnylam (Confirmed — Merck partnership announcement 22 May 2026). This shift could improve R&D efficiency, but it also means future revenue will be more shared.

Investors should monitor Merck’s capital allocation guidance in its Q2 2026 earnings release (scheduled 31 May 2026). A higher R&D spend on collaborations versus internal programs would reinforce the rotation toward partner‑centric models.

Key Developments to Watch

• Merck Q2 2026 earnings call (31 May 2026) — guidance on R&D spend and any new partnership announcements will clarify the company’s strategic direction.
• Gilead’s HIV pipeline update (July 2026) — data on next‑generation long‑acting formulations could expand the market share assumptions used by analysts.
• FDA advisory committee meeting on KRAS inhibitors (September 2026) — outcomes may affect the valuation of remaining KRAS‑targeted candidates across the sector.

Will investors double down on diversified pharma stocks at the expense of niche oncology players, or will the market find new high‑growth targets to fill the void?